BofA warns Fed risks policy mistake with early rate cuts
John Rondoni, the Chief Technology Officer of Inspire Medical Systems, Inc. (NYSE:INSP), recently sold 2,287 shares of the company’s common stock. The transaction, which took place on March 3, 2025, was executed at a price of $185.60 per share, amounting to a total value of approximately $424,467. The sale comes as the stock has declined nearly 8% over the past week, according to InvestingPro data, though the company maintains strong financials with a current ratio of 7.13, indicating robust liquidity.
Following this sale, Rondoni retains ownership of 15,500 shares in the company. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which was established on May 23, 2024. Such plans are often used by executives to manage the sale of stocks in a manner that complies with insider trading regulations. For deeper insights into insider transactions and comprehensive financial analysis, InvestingPro offers detailed reports covering 1,400+ US stocks, including INSP’s latest financial health score of GREAT.
In other recent news, Inspire Medical Systems reported its fourth-quarter earnings, revealing a significant earnings per share (EPS) beat and revenue that met prior expectations. RBC Capital Markets noted that the company’s EPS exceeded consensus estimates by 57%, and Inspire Medical (TASE:BLWV)’s revenue surpassed previous projections by 3%. UBS maintains a Buy rating with a $265 target, highlighting the company’s robust fundamentals and positive cash flow, despite an ongoing Department of Justice investigation. RBC also maintains an Outperform rating with a $260 target, citing the potential impact of the Inspire V product launch on the company’s growth. Meanwhile, Truist Securities adjusted its price target to $235, retaining a Buy rating, and pointed out the company’s solid gross margin and strong financial guidance for 2025.
Morgan Stanley (NYSE:MS) also revised its price target to $220 but kept an Overweight rating, underscoring the company’s profitability and conservative guidance. UBS and other analysts see the ongoing legal scrutiny as typical in the sector and suggest any stock price dips could be buying opportunities. The company’s management remains confident in its market position, bolstered by technological advancements and comprehensive support services. Investors are advised to keep an eye on the ongoing Department of Justice investigation and its potential implications for the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.